Aspen Neuroscience announced a collaboration and license agreement with Cell X Technologies to integrate Cell X’s artificial intelligence and computer vision platform into Aspen’s manufacturing process. According to the company, the partnership is designed to improve quality control for Aspen’s autologous cell therapies targeting Parkinson’s disease.
The company said that the agreement includes licensing of Cell X’s technology, which uses AI to identify and characterize cell populations in real time during manufacturing. Aspen Neuroscience claims this capability can help reduce variability, ensure consistent product quality and potentially accelerate development timelines.
Aspen Neuroscience is developing personalized cell therapies derived from each patient’s own induced pluripotent stem cells to replace dopamine-producing neurons lost to Parkinson’s disease. The company claims the integration of Cell X’s platform supports its goal of delivering safer, high-quality therapies to patients.
The company said that this collaboration complements its existing investments in automation and closed manufacturing systems, which aim to scale production while maintaining rigorous standards. Aspen Neuroscience claims the partnership will help advance its lead candidate, ANPD001, currently being evaluated in the ASPIRO Phase 1/2a clinical trial.
Aspen Neuroscience said it plans to continue exploring innovative technologies to enhance its research and development pipeline for neurodegenerative diseases.
